42 completed, 7 terminated, 5 withdrawn, 4 unknown. 19 Not applicable, 18 Phase 2, 12 Phase 1, 11 Phase 4, 5 Phase 3.
Follow Prazosin: new trials by email Literature Review of Prazosin trials Research Report on Prazosin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Trauma-related Links Between Affective and Metabolic Systems prazosin - Posttraumatic Stress Disorder, Metabolic Syndrome | Phase 4 | Not yet recruiting | VA Office of Research and Development | 70 | 2027-03-01 | 2026-10-15 |
| Brain Blood Vessel Responses to Changes in Blood Flow MRI, Prazosin, Placebo - Magnetic Resonance Imaging, Cerebrovascular Circulation | Phase 2 | Recruiting | University of Wisconsin, Madison | 36 | 2026-02-26 | 2026-09-15 |
| Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort MRI, Prazosin, Placebo - Magnetic Resonance Imaging, Cerebrovascular Circulation | Phase 2 | Recruiting | University of Wisconsin, Madison | 36 | 2025-12-17 | 2026-07-06 |
| A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults Prazosin HCl - Healthy | Phase 1 | Completed | Pfizer | 69 | 2025-11-14 | 2026-05-14 |
| A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Prazosin + cyproheptadine, KT110 - Alcohol Use Disorder | Phase 1 | Completed | Kinnov Therapeutics | 12 | 2024-04-23 | 2025-03-13 |
| A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin Prazosin Oral Tablet - Morality | Phase 4 | Unknown | Sohag University | 80 | 2023-02-01 | 2024-03-01 |
| A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline Propranolol, Prazosin - Post-traumatic Stress Disorder (PTSD) | Phase 1 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 34 | 2022-09-07 | 2024-01-23 |
| Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg - Hypertension, Heart Failure | Phase 1 | Completed | Pfizer | 72 | 2021-09-22 | 2024-07-12 |
| Prazosin for Alcohol Use Disorder With Withdrawal Symptoms Prazosin, 12-Step Facilitation with Relapse Prevention and Contingency Management - Alcohol Withdrawal | Phase 2 | Completed | Yale University | 152 | 2021-07-01 | 2026-09-30 |
| Reducing Cannabis Overuse With Prazosin Prazosin Hydrochloride - Cannabis Dependence, Posttraumatic Stress Disorder | Phase 4 | Completed | VA Puget Sound Health Care System | 11 | 2020-11-09 | 2025-06-15 |
| Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) Prazosin, Standard of care - COVID-19 | Phase 2 | Terminated | Johns Hopkins University | 5 | 2020-05-13 | 2023-04-10 |
| Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault Prazosin, Placebos - Posttraumatic Stress Disorder | Phase 4 | Withdrawn | University of Colorado, Denver | 2020-02-23 | 2025-05-23 | |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects Cyproheptadine, Alpress LP - Alcohol Use Disorder | Phase 2 | Completed | Kinnov Therapeutics | 154 | 2019-11-30 | 2024-04-15 |
| Prazosin Use in Adults With Anxiety Disorders Prazosin - Anxiety, Anxiety Disorders | Phase 1 | Suspended | University of Manitoba | 20 | 2019-05-24 | 2022-11-02 |
| Prazosin for Agitation in Alzheimer's Disease Prazosin, Placebo oral capsule - Alzheimer's Disease, Disruptive Behavior | Phase 2 | Completed | Alzheimer's Disease Cooperative Study (ADCS) | 35 | 2018-10-23 | 2023-02-06 |
| Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests Prazosin, Placebo - Posttraumatic Stress Disorder | Phase 3 | Active not recruiting | VA Office of Research and Development | 87 | 2018-06-04 | 2026-08-14 |
| The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study Prazosin - Cigarette Smoking Toxicity, Nicotine | Phase 1 | Withdrawn | University of Louisville | 2018-03-13 | 2018-07-26 | |
| Effects of Prazosin on the Attention-Enhancing Effects of Nicotine Placebo, Nicotine, Prazosin - no Condition, Basic Science | Not applicable | Withdrawn | University of Maryland, Baltimore | 2018-03-01 | 2019-08-19 | |
| Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder Prazosin, ALPRESS® LP 2,5 et 5 mg - Acute Stress Disorder | Phase 2 | Completed | Hospices Civils de Lyon | 15 | 2017-04-21 | 2026-05-27 |
Showing 20 of 63. Sign in to see all of them.
Stress Disorders, Post-Traumatic (23) · Alcoholism (13) · Sleep Wake Disorders (5) · Combat Disorders (4) · Hypertension (4) · Substance-Related Disorders (4) · Wounds and Injuries (4) · Alzheimer Disease (3) · Anxiety Disorders (3) · Alcohol Drinking (2) · Binge-Eating Disorder (2) · Dementia (2) · Disease (2) · Fibrosis (2) · Parasomnias (2)
Seattle Institute for Biomedical and Clinical Research (9) · VA Office of Research and Development (5) · US Department of Veterans Affairs (4) · Yale University (4) · University of Washington (3) · University of Wisconsin, Madison (3) · Augusta University (2) · Centre for Addiction and Mental Health (2) · Kinnov Therapeutics (2) · Pfizer (2) · University of Pittsburgh (2) · Alzheimer's Disease Cooperative Study (ADCS) (1) · Brian J Lipworth (1) · Cedars-Sinai Medical Center (1) · French National Agency for Research on AIDS and Viral Hepatitis (1)
United States (47) · Canada (4) · France (4) · Belgium (1) · Egypt (1) · India (1) · Spain (1) · United Kingdom (1)
Murray A. Raskind, MD (3) · Murray Raskind, MD (3) · Elaine R Peskind, MD (2) · Jill Barnes, PhD (2) · Adam P Bress, PharmD, MS (1) · Alain Puech (1) · Andrew J. Saxon, MD (1) · Andrew Saxon, MD (1) · Anne Germain, Ph.D. (1) · Bernard Le Foll, MD, PhD (1) · Bernard Le Foll, PhD (1) · Brian K. Auge, M.D. (1) · Brian Lipworth, MD, FRCP (1)
PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 17069768, PMID 17868655, PMID 18426998, PMID 19047577, PMID 19700947, PMID 19738158, PMID 20203244, PMID 22281448, PMID 22289724, PMID 22801444, PMID 23266540, PMID 23846759, PMID 24893322, PMID 27130272, PMID 27320368, PMID 29414272, PMID 29461925, PMID 30153753, PMID 30192326, PMID 33688908, PMID 33891615, PMID 34184246, PMID 34225296, PMID 34932440, PMID 35141873, PMID 35979039, PMID 37085877, PMID 38154074, PMID 38287923, PMID 38597214, PMID 38767196, PMID 39953590, PMID 9369256, PMID 9890307
P20AA017839 (2), 1IK2CX001774-01 (1), 1IK2RX001136-01A2 (1), 1RF1NS117746-01 (1), 2004 (1), 2016 (1), F31AA022845 (1), I21RX002180 (1), K05AA014715 (1), P50AG005136 (1), R01AA017184 (1), R01AA020504 (1), R01AA029113 (1), R01AG018644 (1), R01AG033133 (1)